Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review.
<h4>Background</h4>Chikungunya (CHIKV) is a reemerging arboviral disease and represents a global health threat because of the unprecedented magnitude of its spread. Diagnostics strategies rely heavily on reverse transcriptase-polymerase chain reaction (RT-PCR) and antibody detection by e...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-07-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010067&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539945394241536 |
|---|---|
| author | José Moreira Patrícia Brasil Sabine Dittrich André M Siqueira |
| author_facet | José Moreira Patrícia Brasil Sabine Dittrich André M Siqueira |
| author_sort | José Moreira |
| collection | DOAJ |
| description | <h4>Background</h4>Chikungunya (CHIKV) is a reemerging arboviral disease and represents a global health threat because of the unprecedented magnitude of its spread. Diagnostics strategies rely heavily on reverse transcriptase-polymerase chain reaction (RT-PCR) and antibody detection by enzyme-linked Immunosorbent assay (ELISA). Rapid diagnostic tests (RDTs) are available and promise to decentralize testing and increase availability at lower healthcare system levels.<h4>Objectives</h4>We aim to identify the extent of research on CHIKV RDTs, map the global availability of CHIKV RDTs, and evaluate the accuracy of CHIKV RDTs for the diagnosis of CHIKV.<h4>Eligibility criteria</h4>We included studies reporting symptomatic individuals suspected of CHIKV, tested with CHIKV RDTs, against the comparator being a validated laboratory-based RT-PCR or ELISA assay. The primary outcome was the accuracy of the CHIKV RDT when compared with reference assays.<h4>Sources of evidence</h4>Medline, EMBASE, and Scopus were searched from inception to 13 October 2021. National regulatory agencies (European Medicines Agency, US Food and Drug Administration, and the Brazilian National Health Surveillance Agency) were also searched for registered CHIKV RDTs.<h4>Results</h4>Seventeen studies were included and corresponded to 3,222 samples tested with RDTs between 2005 and 2018. The most development stage of CHIKV RDTs studies was Phase I (7/17 studies) and II (7/17 studies). No studies were in Phase IV. The countries that manufacturer the most CHIKV RDTs were Brazil (n = 17), followed by the United States of America (n = 7), and India (n = 6). Neither at EMA nor FDA-registered products were found. Conversely, the ANVISA has approved 23 CHIKV RDTs. Antibody RDTs (n = 43) predominated and demonstrated sensitivity between 20% and 100%. The sensitivity of the antigen RDTs ranged from 33.3% to 100%.<h4>Conclusions</h4>The landscape of CHIKV RDTs is fragmented and needs coordinated efforts to ensure that patients in CHIKV-endemic areas have access to appropriate RDTs. Further research is crucial to determine the impact of such tests on integrated fever case management and prescription practices for acute febrile patients. |
| format | Article |
| id | doaj-art-033ab584c2b54b7695702ee1f99af5ff |
| institution | Kabale University |
| issn | 1935-2727 1935-2735 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Neglected Tropical Diseases |
| spelling | doaj-art-033ab584c2b54b7695702ee1f99af5ff2025-02-05T05:33:33ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352022-07-01167e001006710.1371/journal.pntd.0010067Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review.José MoreiraPatrícia BrasilSabine DittrichAndré M Siqueira<h4>Background</h4>Chikungunya (CHIKV) is a reemerging arboviral disease and represents a global health threat because of the unprecedented magnitude of its spread. Diagnostics strategies rely heavily on reverse transcriptase-polymerase chain reaction (RT-PCR) and antibody detection by enzyme-linked Immunosorbent assay (ELISA). Rapid diagnostic tests (RDTs) are available and promise to decentralize testing and increase availability at lower healthcare system levels.<h4>Objectives</h4>We aim to identify the extent of research on CHIKV RDTs, map the global availability of CHIKV RDTs, and evaluate the accuracy of CHIKV RDTs for the diagnosis of CHIKV.<h4>Eligibility criteria</h4>We included studies reporting symptomatic individuals suspected of CHIKV, tested with CHIKV RDTs, against the comparator being a validated laboratory-based RT-PCR or ELISA assay. The primary outcome was the accuracy of the CHIKV RDT when compared with reference assays.<h4>Sources of evidence</h4>Medline, EMBASE, and Scopus were searched from inception to 13 October 2021. National regulatory agencies (European Medicines Agency, US Food and Drug Administration, and the Brazilian National Health Surveillance Agency) were also searched for registered CHIKV RDTs.<h4>Results</h4>Seventeen studies were included and corresponded to 3,222 samples tested with RDTs between 2005 and 2018. The most development stage of CHIKV RDTs studies was Phase I (7/17 studies) and II (7/17 studies). No studies were in Phase IV. The countries that manufacturer the most CHIKV RDTs were Brazil (n = 17), followed by the United States of America (n = 7), and India (n = 6). Neither at EMA nor FDA-registered products were found. Conversely, the ANVISA has approved 23 CHIKV RDTs. Antibody RDTs (n = 43) predominated and demonstrated sensitivity between 20% and 100%. The sensitivity of the antigen RDTs ranged from 33.3% to 100%.<h4>Conclusions</h4>The landscape of CHIKV RDTs is fragmented and needs coordinated efforts to ensure that patients in CHIKV-endemic areas have access to appropriate RDTs. Further research is crucial to determine the impact of such tests on integrated fever case management and prescription practices for acute febrile patients.https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010067&type=printable |
| spellingShingle | José Moreira Patrícia Brasil Sabine Dittrich André M Siqueira Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. PLoS Neglected Tropical Diseases |
| title | Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. |
| title_full | Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. |
| title_fullStr | Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. |
| title_full_unstemmed | Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. |
| title_short | Mapping the global landscape of chikungunya rapid diagnostic tests: A scoping review. |
| title_sort | mapping the global landscape of chikungunya rapid diagnostic tests a scoping review |
| url | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010067&type=printable |
| work_keys_str_mv | AT josemoreira mappingthegloballandscapeofchikungunyarapiddiagnostictestsascopingreview AT patriciabrasil mappingthegloballandscapeofchikungunyarapiddiagnostictestsascopingreview AT sabinedittrich mappingthegloballandscapeofchikungunyarapiddiagnostictestsascopingreview AT andremsiqueira mappingthegloballandscapeofchikungunyarapiddiagnostictestsascopingreview |